Filing Details

Accession Number:
0001209191-19-007526
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-05 19:02:36
Reporting Period:
2019-02-04
Accepted Time:
2019-02-05 19:02:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1667633 Forty Seven Inc. FTSV Pharmaceutical Preparations (2834) 474065674
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1743780 H Chris Takimoto C/O Forty Seven, Inc.
1490 O'Brien Drive, Suite A
Menlo Park CA 94025
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-02-04 8,000 $2.02 8,000 No 4 M Direct
Common Stock Disposition 2019-02-04 8,000 $14.86 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2019-02-04 8,000 $0.00 8,000 $2.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
151,741 2026-02-25 No 4 M Direct
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.49 to $15.15, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth this footnote.
  3. 1/4th of the shares subject to the option vested one year after February 8, 2016 and 1/48th of the shares subject to the option vest monthly thereafter, subject to Reporting Person's continuous service as of each such date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase.